Latest Research And Development News

Livium Ltd has secured a A$663,000 R&D tax rebate for its subsidiary VSPC, pushing total FY25 rebates to A$1.4 million and reinforcing its push into advanced battery materials and recycling.

Terragen Holdings has received nearly $1 million in R&D tax incentives, reinforcing its cash position and fueling ongoing development of its innovative agricultural biotech products.

Anteris Technologies has secured regulatory green lights for its pivotal PARADIGM trial and raised $25.2 million in capital, advancing its innovative DurAVR® transcatheter heart valve towards commercialisation.

AdAlta Limited has received a $0.78 million Research and Development Tax Incentive refund for FY2025, using part of it to repay a Radium Capital loan and strengthening its cash position as it nears a key licensing milestone.

Vitasora Health has secured AU$3.56 million from a cornerstone investor, issuing over 118 million shares, while confirming compliance with key regulatory disclosure obligations.

Papyrus Australia reported a $112k net operating cash outflow in October 2025, offset by financing activities and R&D tax incentives, maintaining a runway of over five months. Despite a non-recurring legal expense and an investment write-down, the company remains confident in its operational continuity.

Cann Group Limited has announced a dramatic 81% reduction in core debt alongside a strategic pivot to higher-margin flower products, positioning the company for its first EBITDA-positive year in FY26.

Firebird Metals has secured a key patent for its energy-efficient kiln and announced plans for an Australian Demonstration Plant to commercialise its battery materials technology.

Amplia Therapeutics reported a $4.18 million half-year loss but bolstered its cash reserves with a $27.6 million capital raise to advance clinical trials of its lead drug narmafotinib, showing encouraging interim data in pancreatic cancer.

SDI Limited reported a steady FY2025 with a slight profit increase, driven by growth in aesthetic and whitening products and the launch of its new amalgam replacement, Stela. The company also announced plans for a new factory to boost production capacity.

Algorae Pharmaceuticals has secured a key distribution agreement with global giant Dr. Reddy’s Laboratories to supply the chemotherapy drug Capecitabine in Australia, marking a significant step in its oncology commercialisation strategy.

International Graphite Limited has finalized the purchase of industrial land in Collie, Western Australia, setting the stage for Australia’s first commercial graphite micronising facility amid rising global demand.